𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Fyn : A novel molecular target in cancer

✍ Scribed by Yoshihito D. Saito; Ana R. Jensen; Ravi Salgia; Edwin M. Posadas

Publisher
John Wiley and Sons
Year
2010
Tongue
English
Weight
192 KB
Volume
116
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Fyn is 59‐kDa member of the Src family of kinases that is historically associated with T‐cell and neuronal signaling in development and normal cellular physiology. Whereas Src has been heavily studied in cancer, less attention has been traditionally awarded to the other Src kinases such as Fyn. Our group has shown that Fyn is particularly upregulated in prostate cancer in contrast to the alternative members of the Src family. This suggests that it may mediate several important processes attributed to Src kinases in prostate cancer and other malignancies. These functions include not only cellular growth and proliferation but also morphogenesis and cellular motility. Together, these suggest a role for Fyn in both progression and metastasis. As several agents in clinical development affect Fyn activation, understanding the role that Fyn plays in cancer is of great importance in oncology. Cancer 2010. Β© 2010 American Cancer Society.

πŸ“œ SIMILAR VOLUMES

Fyn is a novel target of (βˆ’)-epigallocat
Fyn is a novel target of (βˆ’)-epigallocatechin gallate in the inhibition of JB6 Cl41 cell transformation
✍ Zhiwei He; Faqing Tang; Svetlana Ermakova; Ming Li; Qing Zhao; Yong-Yeon Cho; We πŸ“‚ Article πŸ“… 2008 πŸ› John Wiley and Sons 🌐 English βš– 368 KB

## Abstract The cancer preventive action of (βˆ’)‐epigallocatechin gallate (EGCG), found in green tea, is strongly supported by epidemiology and laboratory research data. However, the mechanism by which EGCG inhibits carcinogenesis and cell transformation is not clear. In this study, we report that E

Novel targeted therapies in inflammatory
Novel targeted therapies in inflammatory breast cancer
✍ Massimo Cristofanilli πŸ“‚ Article πŸ“… 2010 πŸ› John Wiley and Sons 🌐 English βš– 84 KB πŸ‘ 2 views

## Abstract Inflammatory breast cancer (IBC) accounts for 1% to 5% of all breast cancer cases. Its aggressive biology is characterized by rapid disease progression and poor prognosis. To improve and standardize therapy for IBC, development of novel therapeutics to molecular targets of IBC is key. T

BMI1 as a novel target for drug discover
BMI1 as a novel target for drug discovery in cancer
✍ Liangxian Cao; Jenelle Bombard; Katherine Cintron; Josephine Sheedy; Marla L. We πŸ“‚ Article πŸ“… 2011 πŸ› John Wiley and Sons 🌐 English βš– 889 KB

Growing evidence has demonstrated that clonogenic cancer stem (initiating) cells are responsible for tumor regrowth and disease relapse. Bmi-1 plays a critical role in the self-renewal of adult stem cells. The Bmi-1 protein is elevated in many types of cancers, and experimental reduction of Bmi-1 pr